BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 18, 2004
 |  BioCentury  |  Product Development

A patch for Parkinson's

Schwarz Pharma AG's Neupro rotigotine dopamine receptor agonist for Parkinson's disease may have an advantage over marketed compounds in the same class because it is administered once daily using a patch. By comparison, marketed dopamine receptor agonists are dosed orally three times daily.

Schwarz reported additional Phase III data last week after having applied for marketing authorizations for Neupro in the U.S. and Europe last month. In the U.S. Phase III trial in 351 advanced PD patients, Neupro plus levodopa met the co-primary endpoints of an absolute reduction in the number...

Read the full 444 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >